Massachusetts Financial Services Adds $262M in Gilead Sciences, Inc. ($GILD)

Massachusetts Financial Services has boosted its stake in Gilead Sciences, Inc. (NasdaqGS: GILD) by 48.7%, according to a Form 13F filing with the SEC. The fund added 2,058,305 shares in the quarter, bringing its total holdings to 6,281,609 shares, valued at about $799.2 million as of the filing date.

What Changed in Massachusetts Financial Services' Gilead Sciences Position

The increase in shares reflects a significant boost in confidence from Massachusetts Financial Services. The fund previously held 4,223,304 shares and has now increased its stake to 6,281,609 shares, adding 2,058,305 shares. This move, reported in the latest filing, shows a nearly 49% increase in its position in Gilead Sciences.

Other Institutional Activity in Gilead Sciences

Several other major funds also made changes to their positions in Gilead Sciences. BlackRock, Inc. reduced its holdings by 4,184,605 shares, ending with 119,010,973 shares valued at approximately $16.59 billion. Vanguard Capital Management LLC added a substantial 80,654,776 shares, now holding shares worth about $11.24 billion. FMR LLC increased its position by 6,326,800 shares to a total of 71,906,290 shares, valued at around $10.02 billion. Meanwhile, State Street Corp trimmed its holdings slightly by 381,933 shares, maintaining 59,858,585 shares valued at $8.34 billion.

Gilead Sciences Stock Snapshot

Shares of Gilead Sciences (NasdaqGS: GILD) traded near $127.23. The company has a market cap of approximately $158 billion and a P/E ratio of 17.31, with a forward P/E of 13.16. Gilead's beta is 0.331, indicating lower volatility compared to the market. The stock's 52-week range is between $104.46 and $157.29, with a 50-day moving average of $132.40 and a 200-day moving average of $129.28.

Recent Earnings

Gilead Sciences reported revenue of $29.74 billion with a growth rate of 4.4%. The company's net margin stands at 30.99%, and it has a return on equity of 43.36%. Earnings per share (EPS) were $7.35. The next earnings release is scheduled for August 6, 2026.

Dividend

Gilead Sciences pays an annual dividend rate of $3.28, yielding 2.58%. The dividend payout ratio is 43.4%, providing a steady income stream for investors.

Insider Buying and Selling at Gilead Sciences, Inc.

On June 15, 2026, Andrew Dickinson, Chief Financial Officer, sold 3,000 shares at an average price of $125.40 under a planned sale. Johanna Mercier, Chief Communications and Corporate Affairs Officer, also sold 3,000 shares at $123.92 on the same day. Earlier, on June 10, several executives, including Daniel Patrick O'Day, Chairman & CEO, sold shares, while Dickinson bought 2,796 shares.

Analysts Set New Price Targets

On June 16, 2026, Cantor Fitzgerald reiterated its buy rating with a price target of $155. Maxim Group upgraded the stock to a buy with a target of $165 on May 20, 2026. Truist Securities and RBC Capital maintained their ratings, with targets of $157 and $122, respectively. The consensus among analysts is a buy, with an average price target of $157.57 from 28 opinions.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company based in Foster City, California. It focuses on discovering, developing, and commercializing medicines for areas of unmet medical need. Known for its HIV treatments like Biktarvy and Descovy, the company also offers therapies for hepatitis, cancer, and COVID-19. Led by CEO Daniel Patrick O'Day, Gilead employs around 17,000 people worldwide.

Bottom Line

Massachusetts Financial Services' recent increase in its stake in Gilead Sciences underscores a significant interest in the biopharmaceutical company. While these Form 13F filings are backward-looking, they provide insight into institutional investors' confidence in Gilead's potential. Investors often track such moves to gauge market sentiment and investment trends in the healthcare sector.